167 related articles for article (PubMed ID: 30123267)
1. Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice.
Zheng W; Zhou J; Song S; Kong W; Xia W; Chen L; Zeng T
Int J Endocrinol; 2018; 2018():8309723. PubMed ID: 30123267
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.
Shen T; Xu B; Lei T; Chen L; Zhang C; Ni Z
Exp Ther Med; 2018 Oct; 16(4):3121-3128. PubMed ID: 30214535
[TBL] [Abstract][Full Text] [Related]
4. Micheliolide alleviates hepatic steatosis in db/db mice by inhibiting inflammation and promoting autophagy via PPAR-γ-mediated NF-кB and AMPK/mTOR signaling.
Zhong J; Gong W; Chen J; Qing Y; Wu S; Li H; Huang C; Chen Y; Wang Y; Xu Z; Liu W; Li H; Long H
Int Immunopharmacol; 2018 Jun; 59():197-208. PubMed ID: 29656210
[TBL] [Abstract][Full Text] [Related]
5. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.
Sujishi T; Fukunishi S; Ii M; Nakamura K; Yokohama K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
J Clin Biochem Nutr; 2015 Nov; 57(3):244-53. PubMed ID: 26566312
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
8. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.
Ohyama T; Sato K; Yamazaki Y; Hashizume H; Horiguchi N; Kakizaki S; Mori M; Kusano M; Yamada M
World J Gastroenterol; 2014 Nov; 20(43):16227-35. PubMed ID: 25473177
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Jung YA; Choi YK; Jung GS; Seo HY; Kim HS; Jang BK; Kim JG; Lee IK; Kim MK; Park KG
Diabetes Res Clin Pract; 2014 Jul; 105(1):47-57. PubMed ID: 24842243
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.
Prakash S; Rai U; Kosuru R; Tiwari V; Singh S
Biochimie; 2020 Jan; 168():198-209. PubMed ID: 31715215
[TBL] [Abstract][Full Text] [Related]
11. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
[TBL] [Abstract][Full Text] [Related]
12. A new way for punicalagin to alleviate insulin resistance: regulating gut microbiota and autophagy.
Cao Y; Ren G; Zhang Y; Qin H; An X; Long Y; Chen J; Yang L
Food Nutr Res; 2021; 65():. PubMed ID: 34262422
[TBL] [Abstract][Full Text] [Related]
13. A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.
Nakamura K; Fukunishi S; Yokohama K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2017 Apr; 39(4):969-983. PubMed ID: 28260070
[TBL] [Abstract][Full Text] [Related]
14. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
15. Mangiferin ameliorates fatty liver via modulation of autophagy and inflammation in high-fat-diet induced mice.
Wang H; Zhu YY; Wang L; Teng T; Zhou M; Wang SG; Tian YZ; Du L; Yin XX; Sun Y
Biomed Pharmacother; 2017 Dec; 96():328-335. PubMed ID: 29024899
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
Zhuge F; Ni Y; Nagashimada M; Nagata N; Xu L; Mukaida N; Kaneko S; Ota T
Diabetes; 2016 Oct; 65(10):2966-79. PubMed ID: 27445264
[TBL] [Abstract][Full Text] [Related]
17. Exposure to an environmentally relevant mixture of organochlorine compounds and polychlorinated biphenyls Promotes hepatic steatosis in male Ob/Ob mice.
Mulligan C; Kondakala S; Yang EJ; Stokes JV; Stewart JA; Kaplan BL; Howell GE
Environ Toxicol; 2017 Apr; 32(4):1399-1411. PubMed ID: 27533883
[TBL] [Abstract][Full Text] [Related]
18. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R
Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice.
El-Kashef DH; Serrya MS
Life Sci; 2019 Jul; 228():266-273. PubMed ID: 31077717
[TBL] [Abstract][Full Text] [Related]
20. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
